

## LITERATÚRA

1. ABE Y, SAKAIRI T, KAJIYAMA H, et al. Bioenergetic characterization of mouse podocytes. *Am J Physiol Cell Physiol* 2010, 299: C464–C476. Doi:10.1152/ajp-cell.00563.2009 (citované 15.10.2022).
2. AHOLA-ERKKILÄ S, CARROLL JCH, PELTOLA-MJÖSUND K, et al. Ketogenic diet slows down mitochondrial myopathy progression in mice. *Human Molecular Genetics* 2010, 19: 1974-1984.
3. AL DALBHI SK, ALQARNI FA, BAHATHEQ NM, et al. Mitochondrial dysfunction and kidney disease. *J Nephropathol* 2019, 8 (2): e18. Doi: 10.15171/jnp.2019.18 (citované 30.10.2022).
4. ALEHAGEN U, AASETH J, JOHANSSON P. Less increase of copeptin and MR-pro-ADM due to intervention with selenium and CoQ10 for 4 years- follow up results of a randomised controlled trial in elderly citizens. *Biofactors* 2015, 41: 443-452.
5. ALEHAGEN U, LINDAHL TL, AASETH J, et al. Levels of sP- selectin and hs-CRP decrease with dietary intervention with selenium and CoQ10. *PLOS ONE* 2015, 10: e0137680 (citované 30.10.2022).
6. ANDRES-HERNANDO A, LANASPA MA, KUWABARA M, et al. Obesity causes renal mitochondrial dysfunction and energy imbalance and accelerates chronic kidney disease in mice . *Am J Physiol Renal Physiol* 2019, 317: F941–F948. First published August 14, 2019. Doi:10.1152/ajprenal.00203.2019 (citované 15.10.2022).
7. ARTUCH R, SALVIATI L, JACKSON S, et al. Coenzyme Q10 deficiencies in neuromuscular diseases. *Adv Exp Med Biol* 2009, 652: 117–128.
8. ASCENZI P, COLETTA M, WISON MT, et al. Cardiolipin- cytochrome c complex: switching cytochrome C from an electron-transfer shuttle to a myoglobin and a peroxidase-like heme-protein. *IUBMB Life* 2015, 67 (2): 98–109.
9. AUDZEYENKA I, BIERŻYŃSKA A, LAY AC. Podocyte Bioenergetics in the Development of Diabetic Nephropathy: The Role of Mitochondria. *Endocrinology* 2022, 163 (1): 1–12. Doi.org/10.1210/endocr/bqab234 (citované 15.10.2022).
10. AYANGA BA, BADAL SS, WANG Y, et al. Dynamin-related protein 1 deficiency improves mitochondrial fitness and protects against progression of diabetic nephropathy. *J Am Soc Nephrol* 2016, 27: 2733–2747. Doi:10.1681/ASN.2015101096 (citované 30.10.2022).
11. BADAL SS, DANESH FR. New insights into molecular mechanisms of diabetic kidney disease. *Am J Kidney Dis* 2014, 63 (2 Suppl 2): S63–83.
12. BAI XY, MA Y, DING R, et al. miR-335 and miR-34a promote renal senescence by suppressing mitochondrial antioxidative enzyme. *J Am Soc Nephrol* 2011, 22: 1252–1261.
13. BAKIS H, TRIMOUILLE A, VERMOREL A, et al. Adult onset tubulo-interstitial nephropathy in MT-ND5-related phenotypes. *Clin Genet* 2020, 97: 628–633.
14. BANDIERA S, RUBERG S, GIRARD M, et al. Nuclear outsourcing of RNA interference components to human mitochondria. *PLos One* 2011, 6: e20746. Doi: 10.1371/journal.pone.0020746 (citované 15.10.2022).

15. BAO X, ZHANG J, HUANG G, et al. The crosstalk between HIFs and mitochondrial dysfunctions in cancer development. *Cell Death and Disease* 2021, 12: 215. Doi.org/10.1038/s41419-021-03505-1 (citované 12.9.2022).
  16. BELOSTOTSKY R, BEN-SHALOM E, RINAT C, et al. Mutations in the mitochondrial seryl-tRNA synthetase cause hyperuricemia, pulmonary hypertension, renal failure in infancy and alkalosis, HUPRA syndrome. *Am J Hum Genet* 2011, 88: 193–200.
  17. BENIGNI A, PERICO L, MACCONI D. Mitochondrial dynamics is linked to longevity and protects from end-organ injury: the emerging role of sirtuin 3. *Antioxid Redox Signal* 2016, 25 (4): 185–199.
  18. BHARGAVA P, SCHNELLMANN RG. Mitochondrial energetics in the kidney. *Nature Reviews Nephrology* 2017, 13: 629–646.
  19. BHATIA D, CAPILI A, CHOI ME. Mitochondrial dysfunction in kidney injury, inflammation, and disease: potential therapeutic approaches. *Kidney Res Clin Pract* 2020, 39 (3): 244–258. Doi.org/10.23876/j.krcp.20.082 (citované 12.9.2022).
  20. BIRKUS G, HÁJEK M, KRAMATA P, et al. Tenofovir diphosphate is a poor substrate and a weak inhibitor of rat DNA polymerase  $\alpha$ ,  $\delta$ ,  $\epsilon$ . *Antimicrob Agents Chemother* 2002, 46: 1610–1613.
  21. BRENES LG, SANCHEZ MI. Impaired urinary ammonium excretion in patients with isolated proximal renal tubular acidosis. *J Am Soc Nephrol* 1993, 4: 1073–1078.
  22. BRINKKOETTER PT, BORK T, SALOU S, et al. Anaerobic glycolysis maintains the glomerular filtration barrier independent of mitochondrial metabolism and dynamics. *Cell Rep* 2019, 27: 15511566.e5. Doi:10.1016/j.celrep.2019.04.012 (citované 30.3.2023).
  23. BROOKS C, WEI Q, CHO SG, DONG Z. Regulation of mitochondrial dynamics in acute kidney injury in cell culture and rodent models. *J Clin Invest* 2009, 119 (5): 1275–1285.
  24. BUEMI M, ALLEGRA A, ROTIG A, et al. Renal failure from mitochondrial cytopathies. *Nephron* 1997, 76: 249–253.
  25. CAGIN U, ENRIQUEZ JA. Mitochondrial DNA-related disorders: emphasis on mechanisms and heterogeneity. *Turk J Biol* 2015, 39: 840–855.
  26. CANTO C, MENZIES KJ, AUWERX J. NAD(+) metabolism and the control of energy homeostasis: a balancing act between mitochondria and the nucleus. *Cell Metab* 2015, 22 (1): 31–53.
  27. CASALENA G, KRICK S, DAEHN I, et al. Mpv17 in mitochondria protects podocytes against mitochondrial dysfunction and apoptosis in vivo and in vitro. *Am J Phys Renal Phys* 2014, 306 (11): F1372–1380.
  28. CASALENA GA, YU L, GIL R, et al. The diabetic microenvironment causes mitochondrial oxidative stress in glomerular endothelial cells and pathological crosstalk with podocytes. *Cell Commun Signal* 2020, 18: 105. Doi.org/10.1186/s12964-020-00605-x (citované 12.9.2022).
  29. CASARIN A, JIMENEZ-ORTEGA JC, TREVISSON E, et al. Functional characterization of human COQ4, a gene required for Coenzyme Q10 biosynthesis. *Biochem Biophys Res Commun* 2008, 372: 35–39.
  30. CLARK JB, HAYES DJ, MORGAN-HUGHES JA, BYREN E. Mitochondrial myopathies: disorders of the respiratory chain and oxidative phosphorylation. *J Inher Met Dis* 1984, Suppl 1: 62–68.
-

31. COOMBES JS, FASSETT RG. Antioxidant therapy in hemodialysis patients: a systematic review. *Kidney Int* 2012, 81 (3): 233-246.
  32. COTÉ HCF, MAGIL AB, HARRIS M, et al. Exploring mitochondrial nephrotoxicity as a potential mechanism of kidney dysfunction among HIV-infected patients on highly active antiretroviral therapy. *Antivir Ther* 2006, 11 (1): 79-86.
  33. COUGHLAN MT, HIGGINS GC, NGUYEN TV, et al. Deficiency in apoptosis-inducing factor recapitulates chronic kidney disease via aberrant mitochondrial homeostasis. *Diabetes* 2016, 65: 1085-1098.
  34. COUGHLAN MT, NGUYEN TV, PENFOLD SA, et al. Mapping time-course mitochondrial adaptations in the kidney in experimental diabetes. *Clin Sci (Lond)* 2016b, 130: 711-720.
  35. COUGHLAN MT, SHARMA K. Challenging the dogma of mitochondrial reactive oxygen species overproduction in diabetic kidney disease. *Kidney Int* 2016, 90 (2): 272-279. Doi: 10.1016/j.kint.2016.02.043 (citované 12.9.2022).
  36. D'ACO EK, MANNO M, CLARKE C, et al. Mitochondrial tRNA(Phe) mutation as a cause of end-stage renal disease in childhood. *Pediatr Nephrol* 2013, 28: 515-519.
  37. de LAAT P, van ENGELN N, WETZELS JF, et al. Five non-mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes phenotype adult patients with m.3243A>G mutation after kidney transplantation: follow-up and review of the literature. *Clin Kidney J* 2019, 12: 840-846. Doi: 10.1093/ckj/sfz020 (citované 27.1.2023)
  38. DE LONLAY P, VALNOT I, BARRIENTOS A, et al. A mutant mitochondrial respiratory chain assembly protein causes complex III deficiency in patients with tubulopathy, encephalopathy and liver failure. *Nat Genet* 2001, 29: 57-60.
  39. DE MEIRLEIR L, SENECA S, DAMIS E, et al. Clinical and diagnostic characteristics of complex III deficiency due to mutations in the BCS1L gene. *Am J Med Genet A* 2003, 121A: 126-131.
  40. DI DONATO S. Multisystem manifestations of mitochondrial disorders. *J Neurol* 2009, 256: 693-710.
  41. DINKOVA-KOSTOVA AT, ABRAMOV AY. The emerging role of Nrf2 in mitochondrial function. *Free Radic Biol Med* 2015, 88 (Pt B): 179-188.
  42. DIOMEDI-CAMASSEI F, DI GIANDOMENICO S, SANTORELLI FM, et al. COQ2 nephropathy: a newly described inherited mitochondriopathy with primary renal involvement. *J Am Soc Nephrol* 2007, 18: 2773-2780.
  43. DOIMO M, DESBATS MA, CERQUA C, et al. Genetics of coenzyme q10 deficiency. *Mol Syndromol* 2014, 5 (3-4): 156-162.
  44. DOMONDON M, POLINA I, NIKIFOROVA AB, et al. Renal Glomerular Mitochondria Function in Salt-Sensitive Hypertension. *Front Physiol* 2020, 10: 1588. Doi: 10.3389/fphys.2019.01588 (citované 12.9.2022).
  45. DROSE S, BRANDT U. Molecular mechanisms of superoxide production by the mitochondrial respiratory chain. *Adv Exp Med Biol* 2012, 748: 145-169.
  46. DUANN P, LIANOS EA, MA J, LIN PH. Autophagy, innate immunity and tissue repair in acute kidney injury. *Int J Mol Sci* 2016, 17 (5): E662, p1-19. Doi:10.3390/ijms17050662 (citované 27.1.2023).
- .....

47. DUCASA GM, MITROFANOVA A, FORNONI A. Crosstalk between lipids and mitochondria in diabetic kidney disease. *Curr Diab Rep* 2019, 19: 144. Doi: 10.1007/s11892-019-1263-x (citované 15.10.2022).
  48. DUCASA GM, MITROFANOVA A, MALLELA SK, et al. ATP-binding cassette A1 deficiency causes cardiolipin-driven mitochondrial dysfunction in podocytes. *J Clin Invest* 2019, 129: 3387–3400.
  49. DZÚRIK R, GAZDÍKOVÁ K, ŠTEFÍKOVÁ K, SPUSTOVÁ V. Nefrologické manifestácie mitochondriálnych chorôb. *Čas Lék čes* 2000, 139 (2): 38-41.
  50. EMMA F, BERTINI E, SALVIATI L, MONTINI G. Renal involvement in mitochondrial cytopathies. *Pediatric nephrology* 2012, 27: 539–550.
  51. EMMA F, MONTINI G, PARIKH SM, SALVIATI L. Mitochondrial dysfunction in inherited renal disease and acute kidney injury. *Nat Rev Nephrol* 2016, 12 (5): 267-280. Doi: 10.1038/nrneph.2015.214 (citované 12.9.2022).
  52. FAN HC, LEE HF, YUE CT, CHI CS. Clinical Characteristics of Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-Like Episodes. *Life* 2021, 11: 1111. Doi.org/10.3390/life11111111 (citované 27.1.2023).
  53. FERGUSON MA, VAIDYA VS, BONVENTRE JV. Biomarkers of nephrotoxic acute kidney injury. *Toxicology* 2008, 245 (3): 182–193.
  54. FINSTERER J, NEWSTEAD SM. Renal involvement in mitochondrial disorder *Bratisl Med J* 2023, 124 (2): 158.
  55. FINSTERER J, SCORZA FA. Renal manifestations of primary mitochondrial disorders. *Biomed Rep* 2017, 6 (5): 487–494.
  56. FINSTERER J. Secondary manifestations of mitochondrial disorders. *J Zhejiang Univ Sci B* 2020, 21: 590-592. Doi: 10.1631/jzus.B2000010 (citované 30.10.2022).
  57. FLEMMING N, PERNOUD L, FORBES J, GALLO L. Mitochondrial Dysfunction in Individuals with Diabetic Kidney Disease: A Systematic Review. *Cells* 2022, 11: 2481. Doi.org/10.3390/cells11162481 (citované 12.9.2022).
  58. FLEMMING NB, GALLO LA, FORBES JM. Mitochondrial dysfunction and signaling in diabetic kidney disease: oxidative stress and beyond. *Semin Nephrol* 2018, 38: 101–110. Doi: 10.1016/j.semnephrol.2018.01.001 (citované 30.10.2022).
  59. FOLI A, BENVENUTO F, PICCININI G, et al. Direct analysis of mitochondrial toxicity of antiretroviral drugs. *AIDS* 2001, 15: 1687-1694.
  60. FOUQUE D, HOLT S, GUEBRE-EGZIABHER F, et al. Relationship between serum carnitine, acylcarnitines, and renal function in patients with chronic renal disease. *J Ren Nutr* 2006, 16 (2): 125-131.
  61. FRIEDERICH-PERSSON M, PERSSON P. Mitochondrial angiotensin II receptors regulate oxygen consumption in kidney mitochondria from healthy and type 1 diabetic rats. *Am J Physiol Renal Physiol* 2020, 318: F683–F688.
  62. FU Z, ZHANG J, ZHANG Y. Role of molecular hydrogen in ageing and ageing-related diseases. *Oxidative Medicine and Cellular Longevity* 2022, Article ID 2249749, 17 pages. Doi.org/10.1155/2022/2249749.
  63. GALVAN DL, BADAL SS, LONG J, et al. Real-time in vivo mitochondrial redox assessment confirms enhanced mitochondrial reactive oxygen species in diabetic nephropathy. *Kidney Int* 2017, 92: 1282–1287.
-

64. GALVAN DL, LONG J, GREEN N, et al. Drp1S600 phosphorylation regulates mitochondrial fission and progression of nephropathy in diabetic mice. *J Clin Invest* 2019, 129: 2807–2823. Doi:10.1172/JCI127277 (citované 30.10.2022).
65. Gazdikova K, Gvozdjakova A, Kucharska J, et al. Oxidative stress and plasma concentrations of coenzyme Q10, alpha-tocopherol, and beta-carotene in patients with a mild to moderate decrease of kidney function. *Nephron* 2001a, 88 (3): 285.
66. GAZDÍKOVÁ K, GVOZDJÁKOVÁ A, KUCHARSKÁ J, et al. Účinok koenzýmu Q10 u pacientov s ochoreniami obličiek. *Čas Lék čes* 2001b, 140 (10): 307-310.
67. GAZDÍKOVÁ K, GVOZDJÁKOVÁ A, KUCHARSKÁ J, et al. Vzťah medzi hladinami vybraných antioxidantov a lipidmi u konzervatívne liečených pacientov s nefropatiami. *Ateroskleróza* 2000b, 4 (4): 239-243.
68. GAZDÍKOVÁ K, FOJTOVÁ A, TICHÁ L. Kidney manifestation of mitochondrial disorders. *Bratisl Med J* 2022, 139 (9): 659-671.
69. GAZDIKOVA K, GVOZDJAKOVA A, KUCHARSKA J, et al. Hladiny malóndialdehydu (MDA) a vybraných antioxidantov v plazme u konzervatívne liečených pacientov s chorobami obličiek. *Bratisl Med J* 2000a, 101 (9): 490-494.
70. GAZDÍKOVÁ K, GVOZDJÁKOVÁ A, KUCHARSKÁ J, DZÚRIK R. Vplyv vybraných antioxidantov na lipidové parametre u konzervatívne liečených pacientov s chorobami obličiek. *Aktuality v nefrologii* 2001c, 7: 10-13.
71. GAZDÍKOVÁ K, MOJTO V. Mitochondrial nephrology. In: Gvozdjaková A, Cornélisen G, Singh RB. *Recent Advances in Mitochondrial Medicine and Coenzyme Q10*. NOVA Medical: New York 2018, 155-186.
72. GAZDÍKOVÁ K. Choroby obličiek v ambulancii všeobecného lekára. In Gazdíková a kol. *Všeobecné lekárstvo*. Solen: Bratislava 2021, s.1069-1128.
73. GODOY JR, OESTERITZ S, HANSCHMANN EM, et al. Segment-specific overexpression of redoxins after renal ischemia and reperfusion: protective roles of glutaredoxin 2, peroxiredoxin 3, and peroxiredoxin 6. *Free Radic Biol Med* 2011, 51 (2): 552-561.
74. GOICOECHEA M, DE VINUESA SG, VERDALLES U, et al. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. *Clin J Am Soc Nephrol* 2010, 5 (8): 1388-1393.
75. GOPAL RK, CALVO SE, SHIH AR, et al. Early loss of mitochondrial complex I and rewiring of glutathione metabolism in renal oncocytoma. *Proc Natl Acad Sci USA* 2018, 115: E6283–E6290.
76. GOVERS LP, TOKA HR, HARIRI A, et al. Mitochondrial DNA mutations in renal disease: an overview. *Pediatr Nephrol* 2021, 36: 9–17. Doi.org/10.1007/s00467-019-04404-6 (citované 30.10.2022).
77. GREAVES LC, REEVE AK, TAYLOR RW, TURNBULL DM. Mitochondrial DNA and disease. *J Pathol* 2012, 226: 274-286.
78. GRÜNFELD JP, NIAUDET P, RÖTIG A. Renal involvement in mitochondrial cytopathies. *Nephrol Dial Transplant* 1996, 11: 760-761.
79. GUILLAUSSÉAU PJ, MASSIN P, DUBOIS LAFORGUE D, et al. Maternally inherited diabetes and deafness: A multicenter study. *Ann Intern Med* 2001, 134: 721-728.

80. GUJARATI NA, VASQUEZ JM, BOGENHAGEN DF, MALLIPATTU SK. The complicated role of mitochondria in podocyte. *Am J Physiol Renal Physiol* 2020, 319: F955–F965. Doi: 10.1152/ajprenal.00393.2020 (citované 15.10.2022).
81. GUO K, LU J, HUANG Y, et al. Protective role of PGC-1alpha in diabetic nephropathy is associated with the inhibition of ROS through mitochondrial dynamic remodeling. *PLoS One* 2015, 10 (4): e0125176. Doi: 10.1371/journal.pone.0125176 (citované 12.9.2022).
82. GVOZDJÁKOVÁ A, KUCHARSKÁ J, HLAVATÁ A. Diagnostika mitochondriálnych porúch. In: Gvozdjaková A. Mitochondriálna medicína a koenzým Q10. Herba: Bratislava 2017: 165-175. ISBN 978-80-89631-60-5.
83. GVOZDJÁKOVÁ A, KUCHARSKÁ J, RAUSOVÁ Z, HLAVATÁ A. Methods for diagnosing mitochondrial disturbances. In: Gvozdjaková A, Cornéllisen G, Singh RB. Recent Advances in Mitochondrial Medicine and Coenzyme Q<sub>10</sub>. NOVA Medical: New York 2018: 241-253.
84. GVOZDJÁKOVÁ A, KUCHARSKÁ J, SUMBALOVÁ Z. Perspectives of mitochondrial nephrology. *Lek Obz* 2023, 72 (6): 244–250.
85. GYURÁSZOVÁ M, GURECKÁ R, BÁBÍČKOVÁ J, TÓTHOVÁ Ľ. Oxidative Stress in the Pathophysiology of Kidney Disease: Implications for Noninvasive Monitoring and Identification of Biomarkers *Oxidative Medicine and Cellular Longevity* Volume 2020, Article ID 5478708, 11 pages. Doi.org/10.1155/2020/5478708 (citované 15.10.2022).
86. HALLAN S, SHARMA K. The role of mitochondria in diabetic kidney disease. *Curr Diab Rep* 2016, 16 (7): 61. Doi: 10.1007/s11892-016-0748-0 (citované 27.1.2023).
87. HARGREAVES IP, MANTLE D, MILFORD D. Chronic kidney disease and coenzyme Q10 supplementation. *J Kidney Care* 2019, 4 (2): 82-90.
88. HASEGAWA K, WAKINO S, YOSHIOKA K, et al. Kidney - specific overexpression of Sirt1 protects against acute kidney injury by retaining peroxisome function. *J Biol Chem* 2010, 285 (17): 13045–13056.
89. HEERINGA SF, CHERNIN G, CHAKI M, et al. COQ6 mutations in human patients produce nephrotic syndrome with sensorineural deafness. *J Clin Invest* 2011, 121: 2013-2024.
90. HERVOUET E, GODINOT C. Mitochondrial disorders in renal tumors. *Mitochondrion* 2006, 6: 105-117.
91. HIGGINS GC, COUGHLAN MT. Mitochondrial dysfunction and mitophagy: the beginning and end to diabetic nephropathy? *Br J Pharmacol* 2014, 171 (8): 1917–1942.
92. HODGIN BJ, RASOULPOUR M, MARKOWITZ SG, D'AGATI DV. Very low birth weight is a risk factor for secondary focal segmental glomerulosclerosis. *Clinical J Am Soc Nephrol* 2009, 4: 71–76.
93. HONG Q, ZHANG L, DAS B, et al. Increased podocyte Sirtuin-1 function attenuates diabetic kidney injury. *Kidney Int* 2018, 93: 1330–1343. Doi: 10.1016/j.kint.2017.12.008 (citované 30.10.2022).
94. HONZIK T, TESAROVA M, MAYR JA, et al. Mitochondrial encephalocardiomyopathy with early neonatal onset due to TMEM70 mutation. *Arch Dis Child* 2010, 95: 296–301.

95. HORNE SJ, VASQUEZ JM, GUO Y, et al. Podocyte - specific loss of Kreuppel-like factor 6 increases mitochondrial injury in diabetic kidney disease. *Diabetes* 2018, 67: 2420–2433. Doi:10.2337/db17-0958 (citované 30.10.2022).
96. [https://www.wikiskripta.eu/w/Funkčn%C3%AD\\_morfologie\\_ledvin](https://www.wikiskripta.eu/w/Funkčn%C3%AD_morfologie_ledvin) (citované 9. decembra 2022).
97. HUANG HY, APPEL JL. Supplementation of diets with alpha-tocopherol reduces serum concentrations of gamma- and delta-tocopherol in humans. *J Nutr* 2003, 133: 3137-3140.
98. CHE R, YANGGANG Y, HUANG S, ZHANG A. Mitochondrial dysfunction in the pathophysiology of renal disease. *Am J Physiol Renal Physiol* 2014, 306: F367–F378.
99. CHEN Y, FRY BC, LAYTON AT. Modeling glucose metabolism and lactate production in the kidney. *Math Biosci* 2017, 289: 116–129.
100. CHRISTENSEN M, SCHIFFER TA, GUSTAFSSON H, et al. Metformin attenuates renal medullary hypoxia in diabetic nephropathy through inhibition uncoupling protein-2. *Diabetes Metab Res Rev* 2019, 35: e3091. Doi: 10.1002/dmrr.3091 (citované 27.1.2023).
101. CHUANG PY, CAI W, LI X, et al. Reduction in podocyte SIRT1 accelerates kidney injury in aging mice. *Am J Physiol Renal Physiol* 2017, 313: F621–F628. Doi:10.1152/ajprenal.00255.2017 (citované 30.3.2023).
102. CHUANG PY, XU J, DAI Y, et al. In vivo RNA interference models of inducible and reversible Sirt1 knockdown in kidney cells. *Am J Pathol* 2014, 184: 1940–1956. Doi:10.1016/j.ajpath.2014.03.01 (citované 30.3.2023).
103. IMASAWA T, OBRE E, BELLANCE N, et al. High glucose repatterns human podocyte energy metabolism during differentiation and diabetic nephropathy. *FASEB J* 2017, 31: 294307. Doi: 10.1096/fj.201600293R (citované 30.10.2022).
104. IMASAWA T, TANAKA M, NARUYAMA N, et al. Pathological similarities between low birth weight-related nephropathy and nephropathy associated with mitochondrial cytopathy. *Diagn Pathol* 2014, 9: 181. Doi.org/10.1186/s13000-014-0181-0 (citované 12.9.2022).
105. ISHIKAWA A, KAWARAZAKI H, ANDO K, et al. Renal preservation effect of ubiquinol, the reduced form of coenzyme Q10. *Clin Exp Nephrol* 2011, 15 (1): 30-33.
106. ISLAM KN, O'BYRNE D, DEVARAJ S, et al. Alpha-tocopherol supplementation decreases the oxidative susceptibility of LDL in renal failure patients on dialysis therapy. *Atherosclerosis* 2000, 150: 217-224.
107. IWASAKI N, BABAZONO T, TSUCHIYA K, et al. Prevalence of A-to-G mutation a nucleotide 3243 of the mitochondrial tRNA (Leu/UUR) gene in Japanes patients with diabetes mellitus and end stage renal disease. *J Hum Genet* 2001, 46: 330-334.
108. JANSEN JJ, MAASSEN JA, VAN DER WOUDE FJ, et al. Mutation in mitochondrial tRNA (Leu(UUR)) gene associated with progressive kidney disease. *J Am Soc Nephrol* 1997, 8: 1118–1124.
109. JANSSEN B, HOHENADEL D, BRINKKOETTER P, et al. Carnosine as a protective factor in diabetic nephropathy. *Diabetes* 2005, 54: 2320–2327.
110. JHA JC, BANAL C, CHOW BSM, et al. Diabetes and Kidney Disease: Role of Oxidative Stress. *Antioxidants & Redox Signaling* 2016, 25 (12): 657-684. Doi: 10.1089/ars.2016.6664 (citované 30.10.2022).

111. JIANG M, BAI M, LEI J, et al. Mitochondrial dysfunction and the AKI-to-CKD transition. *Am J Physiol Renal Physiol* 2020, 319: F1105- F1116.
112. JOHANSSON P, DAHLSTRÖM Ö, DAHLSTRÖM U, ALEHAGEN U. Quality of life and more days out of hospital with supplementation with Improved health related selenium and CoQ10 combined. *J Nutr Health Aging* 2015, 19: 870-877.
113. JOHNSON AA, RAY AS, HANES J, et al. Toxicity of antiviral nucleoside analogs and the human mitochondrial DNA polymerase. *J Biol Chem* 2001, 276: 40847-40857.
114. JOHNSON SC, MARTINEZ F, BITTO A. mTOR inhibitors may benefit kidney transplant recipients with mitochondrial diseases. *Kidney Int* 2019, 95: 455-466. Doi: 10.1016/j.kint.2018.08.038 (citované 27.1.2023).
115. KAO MP, ANG DS, GANDY SJ, et al. Allopurinol benefits left ventricular mass and endothelial dysfunction in chronic kidney disease. *J Am Soc Nephrol* 2011, 22: 1382-1389.
116. KAWAKAMI T, GOMEZ IG, REN S, et al. Deficient autophagy results in mitochondrial dysfunction and FSGS. *J Am Soc Nephrol* 2015, 26 (5): 1040-1052.
117. KAZEMIAN P, KAZEMI-BAJESTANI SM, ALHERBISH A, et al. The use of omega-3 polyunsaturated fatty acids in heart failure: a preferential role in patients with diabetes. *Cardiovasc Drugs Ther* 2012, 26 (4): 311-320. Doi: 10.1007/s10557-012-6397-x (citované 27.1.2023).
118. KDIGO 2020. Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. *Kidney Int* 2020, 98 (Suppl 4): S1-S115. Doi: 10.1016/j.kint.2020.06.019 (citované 15.1.2023).
119. KDIGO 2021. Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. *Kidney Int* 2021, 99 (Suppl 3): S1-S87. Doi: 10.1016/j.kint.2020.11.003 (citované 15.1.2023).
120. KHAN NA, GOVINDARAJ P, KANNAN MEENA A, THANGARAJ K. Mitochondrial disorders: Challenges in diagnosis and treatment. *Indian J Med Res* 2015, 141: 13-26.
121. KIM KS, HONG S, AHN HY, PARK ChY. Comparative Efficacy of Lobeglitazone Versus Pioglitazone on Albuminuria in Patients with Type 2 Diabetes Mellitus. *Diabetes Ther* 2021, 12: 171-181. Doi.org/10.1007/s13300-020-00948-1 (citované 27.1.2023).
122. KIYOMIYA KI, MATSUCHITA N, KUREBE M, et al. Mitochondrial cytochrome c oxidase as a target site for cephalosporin antibiotics in renal epithelial cells (LLC-PK(1)) and renal cortex. *Life Sci* 2002, 72: 55-57.
123. KROEMER G, GALLUZZI L, BRENNER C. Mitochondrial membrane permeabilization in cell death. *Physiol Rev* 2007, 87 (1): 99-163.
124. KVAMME E, ROBERG B, TORGNER IA. Effects of mitochondrial swelling and calcium on phosphate-activated glutaminase in pig renal mitochondria. *Eur J Biochem* 1991, 197: 675-680.
125. KWONG LK, KAMZALOV S, REBRIN I, et al. Effects of coenzyme Q<sub>10</sub> administration on its tissue concentrations, mitochondrial oxidant generation, and oxidative stress in the rat. *Free Radic Biol Med* 2002, 33 (5): 627-638.
126. LEBRECHT D, SETZER B, ROHBACH R, WALKER UA. Mitochondrial DNA and its respiratory chain products are defective in doxorubicin nephrosis. *Nephrol Dial Transplant* 2004, 19: 329-336.

127. LEE YH, KIM SH, KANG JM, et al. Empagliflozin attenuates diabetic tubulopathy by improving mitochondrial fragmentation and autophagy. *Am J Physiol Ren Physiol* 2019, 317: F767-F780.
128. LESLIE N, WANG X, PENG Y, et al. Neonatal multiorgan failure due to ACAD9 mutation and complex I deficiency with mitochondrial hyperplasia in liver, cardiac myocytes, skeletal muscle, and renal tubules. *Hum Pathol* 2016, 49: 27-32.
129. LI H, RUAN XZ, POWIS SH, FERNANDO R, et al. EPA and DHA reduce LPS-induced inflammation responses in HK-2 cells: evidence for a PPAR-gamma-dependent mechanism. *Kidney Int* 2005, 67 (3): 867-874.
130. LI SY, PARK J, QIU C, et al. Increasing the level of peroxisome proliferator-activated receptor  $\alpha$  coactivator-1 $\alpha$  in podocytes results in collapsing glomerulopathy. *JCI Insight* 2017, 2: e92930. Doi: 10.1172/jci.insight.92930 (citované 30.10.2022).
131. LI Y, HEPOKOSKI M, GU W, et al. Targeting Mitochondria and Metabolism in Acute Kidney Injury. *J Clin Med* 2021, 10: 3991. Doi.org/ 10.3390/jcm10173991 (citované 15.10.2022).
132. LIN CHS, LEE HT, LEE MH, et al. Role of mitochondrial DNA copy number alteration in human renal cell carcinoma. *Int J Mol Sci* 2016, 17: 814. Doi: 10.3390/ijms17060814 (citované 12.9.2022).
133. LIN PH, DUANN P. Dyslipidemia in Kidney Disorders: Perspectives on Mitochondria Homeostasis and Therapeutic Opportunities. *Front Physiol* 2020, 11: 1050. Doi: 10.3389/fphys.2020.01050 (citované 30.10.2022).
134. LIN XCH, KUO KL. Oxidative stress in chronic kidney disease. *Renal Replacement Therapy* 2018, 53 (4). Doi.org/10.1186/s41100-018-0195-2 (citované 15.10.2022).
135. LIPPA S, COLACICCO L, CALLA C, et al. Coenzyme Q<sub>10</sub> levels, plasma lipids and peroxidation extent in renal failure and in hemodialytic patients. *Molec Aspects Med* 1994, 15: 213-219.
136. LIU HW, KAO HH, WU CH. Exercise training upregulates SIRT1 to attenuate inflammation and metabolic dysfunction in kidney and liver of diabetic db/db mice. *Nutr Metab (Lond)* 2019, 16: 22.
137. LIU R, ZHONG Y, LI X, et al. Role of transcription factor acetylation in diabetic kidney disease. *Diabetes* 2014, 63: 2440-2453. Doi: 10.2337/db13-1810 (citované 30.10.2022).
138. LONG J, BADAL SS, YE Z, et al. Long noncoding RNA Tug1 regulates mitochondrial bioenergetics in diabetic nephropathy. *J Clin Invest* 2016, 126: 4205-4218. Doi: 10.1172/JCI87927 (citované 30.3.2023).
139. LORENZONI PJ, SCOLA RH, KAMOI KAY CS, et al. When should MERRF (myoclonus epilepsy associated with ragged-red fibers) be the diagnosis? *Arq Neuropsiquiatr* 2014, 72 (10): 803-811.
140. LÖWIK MM, HOL FA, STEENBERGEN EJ, et al. Mitochondrial tRNA<sup>Leu</sup> (UUR) mutation in a patient with steroid-resistant nephrotic syndrome and focal segmental glomerulosclerosis. *Nephrol Dial Transplant* 2005, 20: 336-341.
141. MACUNLUOGLU B, ATAKAN A, ARI E, et al. Epicardial fat tissue thickness is correlated with diminished levels of CoQ10, a major antioxidant in hemodialysis patients. *Clin Biochem* 2014, 47: 1231-1234.

142. MALLIPATTU SK, HE JC. The podocyte as a direct target for treatment of glomerular disease? *Am J Phys Renal Phys* 2016, 311 (1): F46–51.
143. MALLIPATTU SK, HORNE SJ, D'AGATI V, et al. Krüppel-like factor 6 regulates mitochondrial function in the kidney. *J Clin Invest* 2015, 125: 1347–1361. Doi: 10.1172/JCI77084 (citované 25.5.2023).
144. MAO, X, WANG, T, LIU Y, et al. N-acetylcysteine and allopurinol confer synergy in attenuating myocardial ischemia injury via restoring HIF-1 $\alpha$ /HO-1 signaling in diabetic rats. *PLoS ONE* 2013, 8 (7): e68949. Doi: 10.1371/journal.pone.0068949 (citované 30.10.2022).
145. MATSUMOTO T, NAKAYAMA N, ISHIDA K. Eicosapentaenoic acid improves imbalance between vasodilator and vasoconstrictor actions of endothelium-derived factors in mesenteric arteries from rats at chronic stage of type 2 diabetes. *J Pharmacol Exp Ther* 2009, 329 (1): 324–334.
146. McDONNELL E, PETERSON BS, BOMZE HM, HIRSCHEY MD. SIRT3 regulates progression and development of diseases of aging. *Trends Endocrinol Metab* 2015, 26 (9): 486–492.
147. MEHTA RL, CERDA J, BURDMANN EA, et al. International Society of Nephrology's Oby25 initiative for acute kidney injury (zero preventable deaths by 2025): a human rights case for nephrology. *Lancet* 2015, 385 (9987): 2616–2643.
148. MEIERHOFER D, MAYR AJ, FOETSCHL U, et al. Decrease of mitochondrial DNA content and energy metabolism in renal cell carcinoma. *Carcinogenesis* 2004, 25: 1005–1010.
149. MENDE CW. Diabetes and kidney disease: the role of sodium-glucose cotransporter-2 (SGLT-2) and SGLT-2 inhibitors in modifying disease outcomes. *Curr Med Res Opin* 2017, 33 (3): 541–551. Doi: org/10.1080/03007995.2016.1271779 (citované 15.10.2022).
150. MENG Q, WONG YT, CHEN J, RUAN R. Age-related changes in mitochondrial function and antioxidative enzyme activity in fischer 344 rats. *Mech Ageing Dev* 2007, 128 (3): 286–292.
151. MIMA A, YASUZAWA T, NAKAMURA T, UESHIMA S. Linagliptin affects IRS1/Akt signaling and prevents high glucose-induced apoptosis in podocytes. *Sci Rep* 2020, 10: 5775. Doi.org/10.1038/s41598-020-62579-7 (citované 30.10.2022).
152. MIMA A: Mitochondria-targeted drugs for diabetic kidney disease. *Heliyon* 2022, 8: e08878. Doi.org/10.1016/j.heliyon.2022.e08878 (citované 30.10.2022).
153. MISE K, GALVAN DK, DANESH FR. Shaping Up Mitochondria in Diabetic Nephropathy. *Kidney* 2020, 3601: 982–992. Doi: org/10.34067/KID.0002352020 (citované 12.9.2022).
154. MOJTO V, GAZDÍKOVÁ K. Diabetes mellitus. In: Gvozdjáková A. Mitochondriálna medicína a koenzým Q10. Herba: Bratislava 2017, s. 89–100. ISBN 978-80-89631-60-5.
155. MOKÁŇ M, OKŠA A, GALAJDA P. Nefroprotektívny účinok gliflozínov u pacientov s diabetickou obličkovou chorobou – výsledky štúdie CREDENCE. *Interná Med* 2019, 19 (9): 325–328.
156. MOLLET J, GIURGEA I, SCHLEMMER D, et al. Prenyldiphosphate synthase, subunit 1 (PDSS1) and OH-benzoate polyprenyltransferase (COQ2) mutations in ubiquino-

- ne deficiency and oxidative phosphorylation disorders. *J Clin Invest* 2007, 117: 765–772.
157. MORIGI M, PERICO L, ROTA C, et al. Sirtuin 3-dependent mitochondrial dynamic improvements protect against acute kidney injury. *J Clin Invest* 2015, 125 (2): 715–726.
158. MUKHOPADHYAY P, HORVATH B, ZSENGELLER Z, et al. Mitochondrial-targeted antioxidants represent a promising approach for prevention of cisplatin-induced nephropathy. *Free Radic Biol Med* 2012, 52 (2): 497–506.
159. MUNTNER P, HE J, ASTOR BC, et al. Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: results from the atherosclerosis risk in communities study. *J Am Soc Nephrol* 2005, 16: 529–538.
160. MURPHY DM, O'HEARN M, CHOU S. Fatal lactic acidosis and acute renal failure after addition of tenofovir to an antiretroviral regimen containing didanosine. *Clin Infect Dis* 2003, 36 (8): 1082–1085. Doi: 10.1086/368313 (citované 12.9.2022).
161. MUTSAERS HA, WILMER MJ, REIJNDERS D, et al. Uremic toxins inhibit renal metabolic capacity through interference with glucuronidation and mitochondrial respiration. *Biochim Biophys Acta* 2013, 1832: 142–150.
162. NAING A, KENCHIAH M, KRISHNAN B, et al. Maternally inherited diabetes and deafness (MIDD): diagnosis and management. *J Diabetes Complicat* 2014, 28 (4): 542–546.
163. NCZI, 2020. [https://data.nczisk.sk/statisticke\\_vystupy/Diabetologia/Cinnost\\_diabetologickych\\_ambulancii\\_v\\_SR\\_2020\\_sprava\\_k\\_publikovanym\\_vystupom.pdf](https://data.nczisk.sk/statisticke_vystupy/Diabetologia/Cinnost_diabetologickych_ambulancii_v_SR_2020_sprava_k_publikovanym_vystupom.pdf). (citované 3.11.2022).
164. NCZI, 2021. [https://data.nczisk.sk/statisticke\\_vystupy/Diabetologia/Cinnost\\_diabetologickych\\_ambulancii\\_v\\_SR\\_2021.pdf](https://data.nczisk.sk/statisticke_vystupy/Diabetologia/Cinnost_diabetologickych_ambulancii_v_SR_2021.pdf) (citované 3.11.2022).
165. NEZU M, SUZUKI N. Roles of Nrf2 in Protecting the Kidney from Oxidative Damage. *Int J Mol Sci* 2020, 21: 2951. Doi:10.3390/ijms21082951 (citované 30.10.2022).
166. NG LE, VINCENT AS, HALLIWELL B, WONG KP. Action of diclofenac on kidney mitochondria and cells. *Biochem Biophys Res Com* 2006, 348: 494–500.
167. NIAUDET P, RÖTIG A. The kidney in mitochondrial cytopathies. *Kidney Int* 1997, 51 (4): 1000–1007.
168. O'BRIEN ES, NUCCI NV, FUGLESTAD B, et al. Defining the apoptotic trigger: the interaction of cytochrome c and cardiolipin. *J Biol Chem* 2015, 290 (52): 30879–30887.
169. O'TOOLE JF. Renal manifestations of genetic mitochondrial disease. *Int J Nephrol Renovasc Dis* 2014, 7: 57–67.
170. OKŠA A, SCHNORER Z, RAŠLOVÁ K, et al. Diabetická nefropatia – chronická choroba obličiek pri diabetes mellitus: diagnostika, prevencia a liečba. Odporúčané postupy Slovenskej nefrologickej spoločnosti a Slovenskej diabetologickej spoločnosti – UPDATE 2021. *Diab Obez* 2021, 21 (Suppl 1): 5–12.
171. OYOUNI AAA, SAGGU S, TOUSSON E, et al. Mitochondrial Nephrotoxicity induced by Tacrolimus (FK-506) and Modulatory Effects of Bacopa monnieri (Farafakh) of Tabuk Region. *Phcog Res* 2019, 11: 24–28. Doi: 10.4103/pr.pr\_100\_18 (citované 30.10.2022).

172. OZAWA S, UEDA S, IMAMURA H, et al. Glycolysis, but not Mitochondria, responsible for intracellular ATP distribution in cortical area of podocytes. *Sci Rep* 2015, 5: 18575. Doi: 10.1038/srep18575 (citované 3.11.2022).
173. PARIKH S, GOLDSTEIN A, KOENIG MK. Diagnosis and management of mitochondrial disease: a consensus statement from the Mitochondrial Medicine Society. *Genet Med* 2015, 1: 689–701.
174. PARIKH S, SANETO R, FALK JM, et al. Modern Approach to the Treatment of Mitochondrial Disease. *Curr Treat Options Neurol* 2009, 11: 414–430.
175. PARIKH SM, YANG Y, HE L, et al. Mitochondrial function and disturbances in the septic kidney. *Semin Nephrol* 2015a, 35 (1): 108–119.
176. PATIL KN, PARAJULI N, MACMILLAN-CROW LA, MAYEUX RP. Inactivation of renal mitochondrial respiratory complex and manganese superoxide dismutase during sepsis: mitochondria-targeted antioxidant mitigates injury. *Am J Physiol Renal Physiol* 2014, 306 (7): F734–F743.
177. PENDERGRAFT 3rd WF, HERLITZ LC, THORNLEY-BROWN D, et al. Nephrotoxic effects of common and emerging drugs of abuse. *Clin J Am Soc Nephrol* 2014, 9 (11): 1996–2005.
178. PERAZELLA MA, LUCIANO RL. Review of select causes of drug-induced AKI. *Expert Rev Clin Pharmacol* 2015, 8 (4): 367–371.
179. PERNAS L, SCORRANO PERNAS L, SCORRANO L. Mito-morphosis: mitochondrial fusion, fission, and cristae remodeling as key mediators of cellular function. *Annu Rev Physiol* 2016, 78: 505–531.
180. PIRKLBAUER M, SCHUPART R, FUCHS L, et al. Unraveling reno-protective effects of SGLT2 inhibition in human proximal tubular cells. *Am J Physiol Renal Physiol* 2019, 316: F449–F462.
181. PLOTNIKOV E, CIARIMBOLI G. Editorial: Mitochondria in Renal Health and Disease. *Front Physiol* 2021, 12: 707175. Doi: 10.3389/fphys.2021.707175 (citované 27.1.2023).
182. PODRINI CH, CASSINA L, BOLETTA A. Metabolic reprogramming and the role of mitochondria in polycystic kidney disease. *Cell Signal* 2020, 67: 109495. Doi: 10.1016/j.cellsig.2019.109495 (citované 3.11.2022).
183. PU D, PEI-HUI L. Mitochondrial damage and kidney disease. Chapter in *Advances in Experimental Medicine and Biology* 2017. Doi: 10.1007/978-3-319-55330-6\_27. <https://www.researchgate.net/publication/317765507> (citované 30.10.2022).
184. PUTTI R, SICA R, MIGLIACCIO V, LIONETTI L. Diet impact on mitochondrial bioenergetics and dynamics. *Front Physiol* 2015, 6: 109. <https://doi.org/10.3389/fphys.2015.00109> (citované 3.11.2022).
185. QI H, CASALENA G, SHI S, et al. Glomerular endothelial mitochondrial dysfunction is essential and characteristic of diabetic kidney disease susceptibility. *Diabetes* 2017, 66: 763–778.
186. QUIROS PM, MOTTIS A, AUWERX J. Mitonuclear communication in homeostasis and stress. *Nat Rev Mol Cell Biol* 2016, 17 (4): 213–226.
187. RALTO KM, PARIKH SM. Mitochondria in acute kidney injury. *Semin Nephrol* 2016, 36 (1): 8–16. Doi: 10.1016/j.semnephrol.2016.01.005 (citované 3.11.2022).
188. RAO M, JABER BL, BALAKRISHNAN VS. Chronic kidney disease and acquired mitochondrial myopathy. *Curr Opin Nephrol Hypertens* 2018, 27 (2): 113–120.
- .....

189. RATLIFF BB, ABDULMAHDI W, PAWAR R, WOLIN MS. Oxidant mechanisms in renal injury and disease. *Antioxid Redox Signal* 2016, 25: 119. Doi: 10.1089/ars.2016.6665 (citované 3.11.2022).
190. RIBEIRO G, ROEHRS M, BAIRROS A, et al. N-acetylcysteine on oxidative damage in diabetic rats. *Drug Chem Toxicol* 2011, 34 (4): 467-474. Doi: 10.3109/01480545.2011.564179 (citované 12.9.2022).
191. ROPER T, HARBER M, JONES G, et al. Delayed diagnoses of mitochondrialcytopathies in patients presenting with endstage kidney disease: two case reports *BMC Nephrology* 2020, 21: 361. Doi.org/10.1186/s12882-020-02002-5 (citované 12.9.2022).
192. ROSCA MG, VAZQUEZ EJ, CHEN Q, et al. Oxidation of fatty acids is the source of increased mitochondrial reactive oxygen species production in kidney cortical tubules in early diabetes. *Diabetes* 2012, 61: 2074–2083.
193. SAHA SP, WHAYNE TF, Jr. Coenzyme Q-10 in human health: supporting evidence? *South Med J* 2016, 109 (1): 17–21.
194. SAMANT SA, ZHANG HJ, HONG Z, et al. SIRT3 deacetylates and activates OPA1 to regulate mitochondrial dynamics during stress. *Mol Cell Biol* 2014, 34 (5): 807–819.
195. SANGHATHAT S, KUSAFUKA T, YONEDA A, et al. Renal cell carcinoma in a pediatric patient with an inherited mitochondrial mutation. *Pediatr Surg Int* 2005, 21 (9): 745–748.
196. SARAFIDIS PA, STAFYLAS PC, GEORGIANOS PI, et al. Effects of Thiazolidinediones on albuminuria and proteinuria in diabetes: a meta-analysis. *Am J Kidney Dis* 2010, 55: 835–847.
197. SHAND JAD, POTTER HC, PILMORE HL, et al. Increased Peripheral Blood Heteroplasmy of the mt.3243A>G Mutation Is Associated with Earlier End-Stage Kidney Disease: A Case Report and Review of the Literature. *Nephron* 2020, 144: 358–362. Doi.org/10.1159/000507732 (citované 15.10.2022).
198. SHARMA K. Obesity and diabetic kidney disease: role of oxidant stress and redox balance. *Antioxid Redox Signal* 2016, 25 (4): 208–216.
199. SCHIJVENS AM, van de KAR NC, BOOTSMA-ROBROEKS ChM, et al. Mitochondrial Disease and the Kidney With a Special Focus on CoQ<sub>10</sub> Deficiency. *Kidney Int Rep* 2020, 5: 2146–2159.
200. SILVER AS, CARDINAL H, COWELL K, et al. Acute kidney injury: preclinical innovations challenges, and opportunities for translation. *Can J Kidney Health Dis* 2015, 2: 30. Doi: 10.1186/s40697-015-0062-9 (citované 30.10.2022).
201. SIMON N, HERTIG A. Alteration of fatty acid oxidation in tubular epithelial cells: from acute kidney injury to renal fibrogenesis. *Front Med (Lausanne)* 2015, 2: 52. Doi: 10.3389/fmed.2015.00052 (citované 3.11.2022).
202. SLEZÁK J, KURA B, FRIMMEL K, et al. Preventive and therapeutic application of molecular hydrogen in situations with excessive production of free radicals. *Physiol Res* 2016, 65 (Suppl. 1): S11 – S28.
203. SMALL DM, COOMBES JS, BENNETT N, et al. Oxidative stress, anti-oxidant therapies and chronic kidney disease. *Nephrology (Carlton)* 2012, 17: 311–321.
204. SMALL DM, GOBE GC. Oxidative stress and antioxidant therapy in chronic kidney and cardiovascular disease. In: Morales-González JA. *Biochemistry, Genetics and*

- Molecular Biology 2013. ISBN 978-953-51-1123-8. Doi.org/10.5772/51923 (citované 27.1.2023).
205. SOLIN ML, PITKANEN S, TAANMAN JW, HOLTHOFER H. Mitochondrial dysfunction in congenital nephrotic syndrome. *Lab Invest* 2000, 80: 1227-1232.
206. SOURRIS KC, HARCOURT BE, TANG PH, et al. Ubiquinone (coenzyme Q10) prevents renal mitochondrial dysfunction in an experimental model of type 2 diabetes. *Free Radic Biol Med* 2012, 52: 716-723.
207. SPUSTOVA V, KRIVOŠÍKOVÁ Z, GAVULOVÁ L, et al. Nephrogenic metabolic acidosis. *Klin Biochem Metabol* 1997, 3: 170-175.
208. STENVINKEL P, CARRERO JJ, AXELSSON J, et al. Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces fit into the uremic puzzle? *Clin J Am Soc Nephrol* 2008, 3: 505-521.
209. SUN J, ZHANG J, TIAN J, et al. Mitochondria in Sepsis-Induced AKI. *J Am Soc Nephrol* 2019, 30 (7): 1151-1161. Doi: 10.1681/ASN.2018111126 (citované 3.11.2022).
210. SUOMALAINEN A. Therapy for mitochondrial disorders: little proof, high research activity, some promise. *Semin Fetal Neonatal Med* 2011, 16: 236-240.
211. SURESHBABU A, RYTER SW, CHOI ME. Oxidative stress and autophagy: Crucial modulators of kidney injury. *Redox Biology* 2015, 4: 208-214. <https://www.researchgate.net/publication/270826042> (citované 12.9.2022).
212. SUZUKI S, HINOKIO Y, OHTOMO M, et al. The effects of coenzyme Q10 treatment on maternally inherited diabetes mellitus and deafness, and mitochondrial DNA 3243 (A to G) mutation. *Diabetologia* 1998, 41: 584-588.
213. SZABOLCS MJ, SEIGLE R, SHANSKE S, et al. Mitochondrial DNA deletion: A cause of chronic tubulointerstitial nephropathy. *Kidney Internat* 1994, 45: 188-196.
214. TAKAGI S, LI J, TAKAGAKI Y, et al. Ipragliflozin improves mitochondrial abnormalities in renal tubules induced by a high-fat diet. *J Diabetes Investig* 2018, 9: 1025-1032.
215. TAKEMURA K, NISHI H, INAGI R. Mitochondrial Dysfunction in Kidney Disease and Uremic Sarco. penia. *Front Physiol* 2020, 11: 565023. Doi: 10.3389/fphys.2020.565023 (citované 12.9.2022).
216. TAMAKI M, MIYASHITA K, WAKINO S, et al. Chronic kidney disease reduces muscle mitochondria and exercise endurance and its exacerbation by dietary protein through inactivation of pyruvate dehydrogenase. *Kidney Int* 2014, 85: 1330-1339.
217. TAYLOR RW, TURNBULL DM. Mitochondrial DNA mutations in human disease. *Nat Rev Genet* 2005, 6 (5): 389-402.
218. THOMAS SR. Inner medullary lactate production and accumulation: a vasa recta model. *Am J Physiol Renal Physiol* 2000, 279: F468-F481.
219. TRAN M, PARIKH SM. Mitochondrial biogenesis in the acutely injured kidney. *Nephron Clin Pract* 2014, 127 (1-4): 42-45
220. TRAN MT, ZSENGELLER ZK, BERG AH, et al. PGC1alpha drives NAD biosynthesis linking oxidative metabolism to renal protection. *Nature* 2016, 531 (7595): 528-532.
221. TSUJI N, TSUJI T, OHASHI N, et al. Role of mitochondrial DNA in septic AKI via toll-like receptor 9. *J Am Soc Nephrol* 2016, 27 (7): 2009-2020.
222. TSUJI N, TSUJI T, OHASHI N, et al. Role of Mitochondrial DNA in Septic AKI via Toll-Like Receptor 9. *J Am Soc Nephrol* 2016, 27 (7): 2009-2020. Doi: 10.1681/ASN.2015040376 (citované 30.10.2022).
- .....

223. TUMUR Z, SHIMIZU H, ENOMOTO A, et al. Indoxyl sulphate upregulates expression of ICAM-1 and MCP-1 by oxidative stress-induced NF-kappaB activation, *Am J Nephrol* 2010, 31 (5): 435–441.
224. UUSIMAA J, EVANS J, SMITH C, et al. Clinical, biochemical, cellular and molecular characterization of mitochondrial DNA depletion syndrome due to novel mutations in the MPV17 gene. *Eur J Hum Genet* 2014, 22 (2): 184–191. Doi: 10.1038/ejhg.2013.112 (citované 15.10.2022).
225. VALNOT I, VON KLEIST-RETZOW JC, BARRIENTOS A, et al. A mutation in the human heme A: farnesyltransferase gene (COX10) causes cytochrome c oxidase deficiency. *Hum Mol Genet* 2000, 9: 1245–1249.
226. VEDRENNE V, GALMICHE L, CHRETIEN D, et al. Mutation in the mitochondrial translation elongation factor EFTs results in severe infantile liver failure. *J Hepatol* 2012, 56: 294–297.
227. VERMA S, SINGH P, KHURANA S, et al. Implications of oxidative stress in chronic kidney disease: a review on current concepts and therapies. *Kidney Res Clin Pract* 2021, 40 (2): 183–203.
228. VODOŠEK HOJS N, BEVC S, EKART R, HOJS R. Oxidative stress markers in chronic kidney disease with emphasis on diabetic nephropathy. *Antioxidants* 2020, 9: 925. Doi:10.3390/antiox9100925 (citované 27.1.2023).
229. WANG W, WANG Y, LONG J, et al. Mitochondrial fission triggered by hyperglycemia is mediated by ROCK1 activation in podocytes and endothelial cells. *Cell Metab* 2012, 15: 186–200. Doi:10.1016/j.cmet.2012.01.009 (citované 25.5.2023).
230. WANG B, ZHUOSHU L, MAO L, et al. Hydrogen: a novel treatment strategy in kidney disease. *Kidney Dis* 2022, 8: 126 – 136. Doi: 10.1159/0005209819 (citované 3.7.2023).
231. WATSON B, KHAN AM, DESMOND AR, BERGMAN S. Mitochondrial DNA mutations in black Americans with hypertension-associated end-stage renal disease. *Am J Kidney Dis* 2001, 3: 529–536.
232. WEI PZ, KWAN BCHH, CHOW KM, et al. Urinary mitochondrial DNA level is an indicator of intra-renal mitochondrial depletion and renal scarring in diabetic nephropathy. *Nephrol Dial Transplant* 2018, 33: 784–788. Doi: 10.1093/ndt/gfx339 (citované 3.11.2022).
233. WEINBERG JM. Mitochondrial biogenesis in kidney disease. *J Am Soc Nephrol* 2011, 22 (3): 431–436.
234. WENG G, ZHOU B, LIU T, et al. Sitagliptin promotes mitochondrial biogenesis in human SH-SY5Y cells by increasing the expression of PGC-1alpha/ NRF1/TFAM. *IUBMB. Life* 2019, 71: 1515–1521.
235. WU M, LI S, YU X, et al. Mitochondrial activity contributes to impaired renal metabolic homeostasis and renal pathology in STZ- induced diabetic mice. *Am J Physiol Renal Physiol* 2019, 317: F593–F605.
236. YAMADA Y, NAKAMURA K, ABE J, et al. Mitochondrial delivery of coenzyme Q10 via systemic administration using a MITO-Porter prevents ischemia/reperfusion injury in the mouse liver. *J Control Release* 2015, 213: 86 – 95.
- .....

237. YAMAGATA K, TOMIDA C, UMEYAMA K, et al. Prevalence of Japanese dialysis patients with an A-to-G mutation at nucleotide 3243 of the mitochondrial tRNA (Leu(UUR) gene. *Nephrol Dial Transplant* 2000, 15: 385-388.
238. YE J, LI J, YU Y, WEI Q, et al. L-carnitine attenuates oxidant injury in HK-2 cells via ROS-mitochondria pathway. *Regul Pept* 2010, 161 (1-3): 58-66.
239. YEUNG CK, BILLINGS FT, CLAESSENS AJ, et al. CoQ10 dose escalation study in hemodialysis patients: safety, tolerability and effect on oxidative stress. *BMC Nephrol* 2015, 16: 183-191.
240. YOKOI H, YANAGITA M. Decrease of muscle volume in chronic kidney disease: the role of mitochondria in skeletal muscle. *Kidney Int* 2014, 85 (6): 1258-1260.
241. YU JH, LIM SW, LUO K, et al. Coenzyme Q<sub>10</sub> alleviates tacrolimus-induced mitochondrial dysfunction in kidney. *FASEB J* 2019, 33: 12288-12298.
242. Yuan Y, Zhang A, Huang S, et al. A PPAR- $\gamma$  agonist inhibits aldosterone-induced mesangial cell proliferation by blocking ROS-dependent EGFR intracellular signaling. *Am J Physiol Renal Physiol* 2011, 300: F393-F402.
243. YUAN Y, ZHANG A, QI J, et al. p53/Drp1-dependent mitochondrial fission mediates aldosterone-induced podocyte injury and mitochondrial dysfunction. *Am J Physiol Renal Physiol* 2018, 314: F798-F808. Doi:10.1152/ajprenal.00055.2017 (citované 30.10.2022).
244. ZHAN M, BROOKS C, LIU F, et al. Mitochondrial dynamics: regulatory mechanisms and emerging role in renal pathophysiology. *Kidney Int* 2013, 83 (4): 568-581.
245. ZHAO S, WU W, LIAO J, et al. Molecular mechanisms underlying the renal protective effects of coenzyme Q10 in acute kidney injury. *Cell Mol Biol Lett* 2022, 27: 57. Doi.org/10.1186/s11658-022-00361-5 (citované 27.1.2023).
246. ZHOU Q, WU S, JIANG J, et al. Accumulation of circulating advanced oxidation protein products is an independent risk factor for ischemic heart disease in maintenance hemodialysis patients. *Nephrology (Carlton)* 2012, 17: 642-649.
247. ZHU C, XUAN X, CHE R, et al. Dysfunction of the PGC-1 $\alpha$ -mitochondria axis confers adriamycin-induced podocyte injury. *Am J Physiol Renal Physiol* 2014, 306: F1410-F1417. Doi: 10.1152/ajprenal.00622.2013 (citované 30.3.2023).
248. ZHU C, HUANG S, YUANN Y, et al. Mitochondrial dysfunction mediates aldosterone-induced podocyte damage: a therapeutic target of PPAR $\gamma$ . *Am J Pathol* 2011, 178: 2020-2031.
249. ZUK A, BONVENTRE JV. Acute kidney injury. *Annu Rev Med* 2016, 67: 293-307.
250. ZWACKA RM, REUTER A, PFAFF E, et al. The glomerulosclerosis gene Mpv17 encodes a peroxisomal protein producing reactive oxygen species. *EMBO J* 1994, 13 (21): 5129-5334.
- .....